Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AH 001

Drug Profile

AH 001

Alternative Names: AH-001

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnHorn Medicines
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Ubiquitin-protein ligase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alopecia

Most Recent Events

  • 08 May 2024 Adverse events and pharmacodynamics data from preclinical trials in Alopecia presented at the American Academy of Dermatology annual Meeting 2024 (AAD-2024)
  • 20 Dec 2023 AH 001 is available for licensing as of 20 Dec 2023. https://www.anhornmed.com/focus-area/#Pipelines
  • 20 Dec 2023 AnHorn Medicines announces intention to submit IND application of AH 001 for the treatment of androgenetic alopecia in the fourth quarter of 2024 (AnHorn Medicines pipeline, December 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top